These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29503110)

  • 1. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Vaccine; 2018 Mar; 36(14):1816-1822. PubMed ID: 29503110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.
    Palmu AA; Jokinen J; Nieminen H; Syrjänen R; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Lancet Respir Med; 2014 Sep; 2(9):717-27. PubMed ID: 25127244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Borys D; Lommel P; Traskine M; Moreira M; Schuerman L; Kilpi TM
    Lancet Infect Dis; 2014 Mar; 14(3):205-12. PubMed ID: 24287186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of the 10-valent pneumococcal conjugate vaccine among girls, boys, preterm and low-birth-weight infants - Results from a randomized, double-blind vaccine trial.
    Nieminen H; Rinta-Kokko H; Jokinen J; Puumalainen T; Moreira M; Borys D; Schuerman L; Palmu AA
    Vaccine; 2019 Jun; 37(28):3715-3721. PubMed ID: 31122856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
    Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM
    Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial.
    Rinta-Kokko H; Palmu AA; Ruokokoski E; Nieminen H; Moreira M; Schuerman L; Borys D; Jokinen J
    PLoS One; 2022; 17(1):e0261750. PubMed ID: 34986178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the Ten-valent Pneumococcal Conjugate Vaccine Against Tympanostomy Tube Placements in a Cluster-randomized Trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Traskine M; Moreira M; Borys D; Schuerman L; Kilpi TM
    Pediatr Infect Dis J; 2015 Nov; 34(11):1230-5. PubMed ID: 26284652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
    Kilpi TM; Jokinen J; Puumalainen T; Nieminen H; Ruokokoski E; Rinta-Kokko H; Traskine M; Lommel P; Moreira M; Ruiz-Guinazu J; Borys D; Schuerman L; Palmu AA
    Vaccine; 2018 Sep; 36(39):5891-5901. PubMed ID: 30145098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial.
    Palmu AA; Toropainen M; Kaijalainen T; Siira L; Lahdenkari M; Nieminen H; Syrjänen RK; Kilpi TM; Jokinen J
    Pediatr Infect Dis J; 2017 Dec; 36(12):1193-1200. PubMed ID: 28737627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
    Karppinen S; Toivonen L; Schuez-Havupalo L; Teros-Jaakkola T; Waris M; Auranen K; Palmu AA; Peltola V
    Vaccine; 2019 May; 37(22):2935-2941. PubMed ID: 31027929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.
    Palmu AA; Kilpi TM; Rinta-Kokko H; Nohynek H; Toropainen M; Nuorti JP; Jokinen J
    Pediatrics; 2015 Jul; 136(1):e22-7. PubMed ID: 26077477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
    Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
    PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
    Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
    Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.
    Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Neuzil KM; O'Brien KL; Wunderink RG; Grobbee DE; Bonten MJM; Jodar L
    Vaccine; 2019 Sep; 37(38):5777-5787. PubMed ID: 29861177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J
    Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
    Wei SH; Chiang CS; Chiu CH; Chou P; Lin TY
    Pediatr Infect Dis J; 2015 Mar; 34(3):e71-7. PubMed ID: 25247584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of Streptococcus pneumoniae in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish county.
    Littorin N; Ahl J; Uddén F; Resman F; Riesbeck K
    BMC Infect Dis; 2016 Aug; 16(1):407. PubMed ID: 27514843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.